bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figure 7 from Precision Chemoradiotherapy for HER2 Tumors Using Antibody Conjugates of an Auristatin Derivative with Reduced Cell Permeability
Authors: Hingorani Dina V. , Doan Matthew K. , Camargo Maria F. , Aguilera Joseph , Song Seung M. , Pizzo Donald , Scanderbeg Daniel J. , Cohen Ezra E.W. , Lowy Andrew M. , Adams Stephen R. , Advani Sunil J.
Published: April 2023

Effect of auristatin antibody drug conjugates in combination with IR on mouse body weight.
Supplementary Figures from ONC201 Demonstrates Antitumor Effects in Both Triple-Negative and Non–Triple-Negative Breast Cancers through TRAIL-Dependent and TRAIL-Independent Mechanisms
Authors: Ralff Marie D. , Kline Christina L.B. , Küçükkase Ozan C. , Wagner Jessica , Lim Bora , Dicker David T. , Prabhu Varun V. , Oster Wolfgang , El-Deiry Wafik S.
Published: April 2023

Supplementary Figures
Supplementary Figure Legends from ONC201 Demonstrates Antitumor Effects in Both Triple-Negative and Non–Triple-Negative Breast Cancers through TRAIL-Dependent and TRAIL-Independent Mechanisms
Authors: Ralff Marie D. , Kline Christina L.B. , Küçükkase Ozan C. , Wagner Jessica , Lim Bora , Dicker David T. , Prabhu Varun V. , Oster Wolfgang , El-Deiry Wafik S.
Published: April 2023

Supplementary Figure Legends
Supplementary Table 2 from Expression Levels of Therapeutic Targets as Indicators of Sensitivity to Targeted Therapeutics
Authors: Roy Riti , Winteringham Louise N. , Lassmann Timo , Forrest Alistair R.R.
Published: April 2023

Supplementary table 2 shows Spearman correlation values between drug sensitivity and gene expression for 481 drugs studied in the CTRP dataset.
Figure S5 from RAC1b Overexpression Confers Resistance to Chemotherapy Treatment in Colorectal Cancer
Authors: Goka Erik T. , Chaturvedi Pallavi , Lopez Dayrelis T. Mesa , Garza Adriana De La , Lippman Marc E.
Published: April 2023

Figure S5. HCT116 cells were treated with different dose of 5FU (6.25, 12.5, 25 Î¼M) for 72hrs. The cells were lysed in RIPA lysis buffer. 50 Î¼g of protein was resolved on SDS-PAGE gel, transferred on the nitrocellulose member. The membrane was probed with Rac1b, Rac1 and actin antibodies.
Supplementary Figure 2 from Therapeutic and Prophylactic Antitumor Activity of an Oral Inhibitor of Fucosylation in Spontaneous Mammary Cancers
Authors: Disis Mary L. , Corulli Lauren R. , Gad Ekram A. , Koehnlein Marlese R. , Cecil Denise L. , Senter Peter D. , Gardai Shyra J. , Okeley Nicole M.
Published: April 2023

Representative flow cytometry panels are shown for a single CD4 (A, B), CD8 (C, D), NK (E, F), Untreated (G) or CD22 (H) treated animal before treatments began (A, C, E, G) or after treatment with respective antibodies (B, D, F, H).
Supplementary Figure S1 from A Pilot Study of Galunisertib plus Stereotactic Body Radiotherapy in Patients with Advanced Hepatocellular Carcinoma
Authors: Reiss Kim A. , Wattenberg Max M. , Damjanov Nevena , Prechtel Dunphy Elizabeth , Jacobs-Small Mona , Lubas M. Judy , Robinson James , Dicicco Lisa , Garcia-Marcano Luis , Giannone Michael A. , Karasic Thomas B. , Furth Emma E. , Carpenter Erica L. , Wojcieszynski Andrzej P. , Vonderheide Robert H. , Beatty Gregory L. , Ben-Josef Edgar
Published: April 2023

Unsupervised clustering analysis of baseline leukcoytes
Supplementary Information from SLC7A11 Is a Superior Determinant of APR-246 (Eprenetapopt) Response than TP53 Mutation Status
Authors: Fujihara Kenji M. , Corrales Benitez Mariana , Cabalag Carlos S. , Zhang Bonnie Z. , Ko Hyun S. , Liu David S. , Simpson Kaylene J. , Haupt Ygal , Lipton Lara , Haupt Sue , Phillips Wayne A. , Clemons Nicholas J.
Published: April 2023

Supplemental Table 1, 2, 3. Supplemental Materials and Methods.
Supplementary Figure S4 from Nonclinical Development of Next-generation Site-specific HER2-targeting Antibody–drug Conjugate (ARX788) for Breast Cancer Treatment
Authors: Nagaraja Shastri Prathap , Zhu Jingjing , Skidmore Lillian , Liang Xuejun , Ji Yanping , Gu Yi , Tian Feng , Yao Sulan , Xia Gang
Published: April 2023

Supplementary Figure S4 illustrates clinical chemistry changes in ALT and AST levels in male and female monkeys after repeat dose administration of ARX788. ARX788 was administered by intravenous infusion to cynomolgus monkeys at doses of 3.3 mg/kg/dose, 10 mg/kg/dose, or 15 mg/kg/dose once every 3 weeks for 4 total doses. The control group was administered placebo on the same repeat dose schedule. The animals treated with 15 mg/kg/dose did not receive the third and fourth doses due to unexpected mortality and toxicity observed after the second dose. ALT levels in male (A) and female (B) monkeys, and AST levels in male (C) and female (D) monkeys, were measured before dosing and at multiple time points throughout the study.
Supplementary Figure Legends and Table S6 from CRISPR Screening Identifies WEE1 as a Combination Target for Standard Chemotherapy in Malignant Pleural Mesothelioma
Authors: Xu Duo , Liang Shun-Qing , Yang Haitang , Bruggmann Rémy , Berezowska Sabina , Yang Zhang , Marti Thomas Michael , Hall Sean Ralph Robert , Gao Yanyun , Kocher Gregor J. , Schmid Ralph A. , Peng Ren-Wang
Published: April 2023

Supplementary Figure Legends for S1-5 and Table S6 shows the primary antibodies used in this study.
Figure S4 from CRISPR Screening Identifies WEE1 as a Combination Target for Standard Chemotherapy in Malignant Pleural Mesothelioma
Authors: Xu Duo , Liang Shun-Qing , Yang Haitang , Bruggmann Rémy , Berezowska Sabina , Yang Zhang , Marti Thomas Michael , Hall Sean Ralph Robert , Gao Yanyun , Kocher Gregor J. , Schmid Ralph A. , Peng Ren-Wang
Published: April 2023

Supplementary Figure S4. WEE1 inhibitor AZD1775 synergizes with standard chemotherapy in MPM cells
Supplemental Table 2 from The Landscape of Glycogen Synthase Kinase-3 Beta Genomic Alterations in Cancer
Authors: Borden Brittany A. , Baca Yasmine , Xiu Joanne , Tavora Fabio , Winer Ira , Weinberg Benjamin A. , Vanderwalde Ari M. , Darabi Sourat , Korn W. Michael , Mazar Andrew P. , Giles Francis J. , Crawford Lorin , Safran Howard , El-Deiry Wafik S. , Carneiro Benedito A.
Published: April 2023

Association between mismatch repair deficiency and differences in PD-L1 expression between GSK-3B-mutated and GSK-3B-wild type tumors
Supplementary Figures from Targeting Casein Kinase 1 Delta Sensitizes Pancreatic and Bladder Cancer Cells to Gemcitabine Treatment by Upregulating Deoxycytidine Kinase
Authors: Vena Francesca , Bayle Simon , Nieto Ainhoa , Quereda Victor , Aceti Massimiliano , Frydman Sylvia M. , Sansil Samer S. , Grant Wayne , Monastyrskyi Andrii , McDonald Patricia , Roush William R. , Teng Mingxiang , Duckett Derek
Published: April 2023

Supplementary figures 1 through 8.
Supplementary Figures 1-5, and Supplementary Tables 1-3. from KITlow Cells Mediate Imatinib Resistance in Gastrointestinal Stromal Tumor
Authors: Banerjee Sudeep , Yoon Hyunho , Ting Stephanie , Tang Chih-Min , Yebra Mayra , Wenzel Alexander T. , Yeerna Huwate , Mesirov Jill P. , Wechsler-Reya Robert J. , Tamayo Pablo , Sicklick Jason K.
Published: April 2023

Supplementary FIG. 1 IM increases expression of stem markers and decreases KIT in human GIST. Supplementary FIG. 2 Cell cycle analysis of KITHigh and KITLow cells. Supplementary FIG. 3 TKI treatment enriches for KITlow GIST cells additional data. Supplementary FIG. 4 KITlow cells have higher engraftment potential in vivo. Supplementary FIG. 5 Creation of the GIST Onco-GPS map. Supplementary Table 1. Reagent and Oligonucleotides. Supplementary Table 2: GIST-relevant gene sets that provided input genes for the Non-Negative Matrix Factorization (NMF) decomposition. Supplementary Table 3. Antibody screening panel for cell surface markers.
Figure S5 from Blockade of Cell Volume Regulatory Protein NKCC1 Increases TMZ-Induced Glioma Apoptosis and Reduces Astrogliosis
Authors: Luo Lanxin , Guan Xiudong , Begum Gulnaz , Ding Dawei , Gayden Jenesis , Hasan Md Nabiul , Fiesler Victoria M. , Dodelson Jacob , Kohanbash Gary , Hu Baoli , Amankulor Nduka M. , Jia Wang , Castro Maria G. , Sun Baoshan , Sun Dandan
Published: April 2023

Fig. S5. No downregulation in protein expression of GFAP and NKCC1 was found in immunodeficient SB28-GFP tumors in peri-tumor layer 3.
Figure S4 from Blockade of Cell Volume Regulatory Protein NKCC1 Increases TMZ-Induced Glioma Apoptosis and Reduces Astrogliosis
Authors: Luo Lanxin , Guan Xiudong , Begum Gulnaz , Ding Dawei , Gayden Jenesis , Hasan Md Nabiul , Fiesler Victoria M. , Dodelson Jacob , Kohanbash Gary , Hu Baoli , Amankulor Nduka M. , Jia Wang , Castro Maria G. , Sun Baoshan , Sun Dandan
Published: April 2023

Fig. S4. Morphology analysis of astrocytes in peri-tumor regions in vehicle control mice and astrocytes in layer 3 in response to four different treatments (Vehicle control, TMZ, BMT, T+B).
Supplementary Data from Cabozantinib Unlocks Efficient In Vivo Targeted Delivery of Neutrophil-Loaded Nanoparticles into Murine Prostate Tumors
Authors: Chaudagar Kiranj Kishor , Landon-Brace Natalie , Solanki Aniruddh , Hieromnimon Hanna M. , Hegermiller Emma , Li Wen , Shao Yue , Joseph John , Wilkins Devan J. , Bynoe Kaela M. , Li Xiang-Ling , Clohessy John G. , Ullas Soumya , Karp Jeffrey M. , Patnaik Akash
Published: April 2023

Need as per reviewer suggestion
Figure S1 from Blockade of Cell Volume Regulatory Protein NKCC1 Increases TMZ-Induced Glioma Apoptosis and Reduces Astrogliosis
Authors: Luo Lanxin , Guan Xiudong , Begum Gulnaz , Ding Dawei , Gayden Jenesis , Hasan Md Nabiul , Fiesler Victoria M. , Dodelson Jacob , Kohanbash Gary , Hu Baoli , Amankulor Nduka M. , Jia Wang , Castro Maria G. , Sun Baoshan , Sun Dandan
Published: April 2023

Fig. S1. Full-length western blots of glioma cells, mouse tissue and human tissue samples.
Supplementary Data from Preclinical Assessment of a MUC12-Targeted BiTE (Bispecific T-cell Engager) Molecule
Authors: Pham Elizabeth , Friedrich Matthias , Aeffner Famke , Lutteropp Michael , Mariano Natalie F. , Deegen Petra , Dahlhoff Christoph , Vogel Franziska , Bluemel Claudia , Harrold John M. , Brandl Christian , Grinberg Natalia , Rattel Benno , Coxon Angela , Bailis Julie M.
Published: April 2023

Includes supplemental methods, tables and figures.
Supplementary Table S1 from Tipifarnib as a Precision Therapy for HRAS-Mutant Head and Neck Squamous Cell Carcinomas
Authors: Gilardi Mara , Wang Zhiyong , Proietto Marco , Chillà Anastasia , Calleja-Valera Juan Luis , Goto Yusuke , Vanoni Marco , Janes Matthew R. , Mikulski Zbigniew , Gualberto Antonio , Molinolo Alfredo A. , Ferrara Napoleone , Gutkind J. Silvio , Burrows Francis
Published: April 2023

Supplementary table 1. Top tipifarnib modulated genes used for ENRICHR GSEA.
Supplementary Information from Repurposing the Antidepressant Sertraline as SHMT Inhibitor to Suppress Serine/Glycine Synthesis–Addicted Breast Tumor Growth
Authors: Geeraerts Shauni Lien , Kampen Kim Rosalie , Rinaldi Gianmarco , Gupta Purvi , Planque Mélanie , Louros Nikolaos , Heylen Elien , De Cremer Kaat , De Brucker Katrijn , Vereecke Stijn , Verbelen Benno , Vermeersch Pieter , Schymkowitz Joost , Rousseau Frederic , Cassiman David , Fendt Sarah-Maria , Voet Arnout , Cammue Bruno P.A. , Thevissen Karin , De Keersmaecker Kim
Published: April 2023

This file describes all yeast experiments and includes supplementary tables S1-S3 and supplementary figures S1-S10.
Supplementary Data from Tipifarnib as a Precision Therapy for HRAS-Mutant Head and Neck Squamous Cell Carcinomas
Authors: Gilardi Mara , Wang Zhiyong , Proietto Marco , Chillà Anastasia , Calleja-Valera Juan Luis , Goto Yusuke , Vanoni Marco , Janes Matthew R. , Mikulski Zbigniew , Gualberto Antonio , Molinolo Alfredo A. , Ferrara Napoleone , Gutkind J. Silvio , Burrows Francis
Published: April 2023

Supplementary Materials and Methods
Table S3 from An Emerging Landscape for Canonical and Actionable Molecular Alterations in Primary and Metastatic Prostate Cancer
Authors: Dawson Nancy A. , Zibelman Matthew , Lindsay Timothy , Feldman Rebecca A. , Saul Michelle , Gatalica Zoran , Korn W. Michael , Heath Elisabeth I.
Published: April 2023

characterization of frequently mutated genes in MSI-H
Supplementary Data Table S2 from An Emerging Landscape for Canonical and Actionable Molecular Alterations in Primary and Metastatic Prostate Cancer
Authors: Dawson Nancy A. , Zibelman Matthew , Lindsay Timothy , Feldman Rebecca A. , Saul Michelle , Gatalica Zoran , Korn W. Michael , Heath Elisabeth I.
Published: April 2023

somatic mutations associated with genomic landscape measures
Supplementary Figures from Tankyrase Inhibitors Target Colorectal Cancer Stem Cells via AXIN-Dependent Downregulation of c-KIT Tyrosine Kinase
Authors: Jang Myung-Kyu , Mashima Tetsuo , Seimiya Hiroyuki
Published: April 2023

Supplementary Figure 1 shows morphology, growth and plasticity of the CD44-positive and -negative COLO-320DM cells. Supplementary Figure 2 shows that tankyrase inhibitors preferentially target CD44-positive COLO-320DM cells. Supplementary Figure 3 shows that tankyrase inhibitors decrease the CD44-positive cell populations in colorectal cancer cells. Supplementary Figure 4 shows that tankyrase inhibitors upregulate AMOTL1 to comparable levels in CD44-positive and -negative COLO-320DM cells. Supplementary Figure 5 shows c-KIT expression in colorectal cancer cell lines. Supplementary Figure 6 shows that c-KIT depletion inhibits proliferation of CD44-positive COLO-320DM cells. Supplementary Figure 7 shows difficulties in detecting c-KIT phosphorylation in colorectal cancer cells under the normal growth conditions. Supplementary Figure 8 shows c-KIT phosphorylation induced by stem cell factor in CD44-positive COLO-320DM cells and its downregulation by tankyrase inhibitors. Supplementary Figure 9 shows that c-KIT overexpression strengthens resistance of DLD-1 cells to tankyrase inhibitors. Supplementary Figure 10 shows that G007-LK does not significantly destabilize c-KIT protein in COLO-320DM cells. Supplementary Figure 11 shows negative effect of imatinib on CD44-positive cell populations in COLO-320DM and DLD-1 cells. Supplementary Figure 12 shows that AXIN2 knockdown blocks c-KIT downregulation in G007-LK-treated colorectal cancer cells. Supplementary Figure 13 shows that G007-LK does not affect the stability of c-KIT mRNA in COLO-320DM and DLD-1 cells. Supplementary Figure 14 shows that tankyrase inhibitors downregulate c-KIT promoter activity in an AXIN2-dependent manner in DLD-1 cells. Supplementary Figure 15 shows that tankyrase inhibitors do not significantly downregulate SP1 protein levels in COLO-320DM and DLD-1 cells. Supplementary Figure 16 shows that tankyrase inhibitors downregulate JNK phosphorylation levels in CD44-positive COLO-320DM cells. Supplementary Figure 17 shows that G007-LK upregulates AXIN2 and downregulates c-KIT in vivo. Supplementary Figure 18 shows that tankyrase inhibitors do not enhance the therapeutic efficacy of irinotecan on DLD-1 xenograft tumors in vivo.
Supplementary Data Figure S2 from An Emerging Landscape for Canonical and Actionable Molecular Alterations in Primary and Metastatic Prostate Cancer
Authors: Dawson Nancy A. , Zibelman Matthew , Lindsay Timothy , Feldman Rebecca A. , Saul Michelle , Gatalica Zoran , Korn W. Michael , Heath Elisabeth I.
Published: April 2023

JAK1 mutation frequency across tumors
Supplementary Data Figure S1 from An Emerging Landscape for Canonical and Actionable Molecular Alterations in Primary and Metastatic Prostate Cancer
Authors: Dawson Nancy A. , Zibelman Matthew , Lindsay Timothy , Feldman Rebecca A. , Saul Michelle , Gatalica Zoran , Korn W. Michael , Heath Elisabeth I.
Published: April 2023

oncoprint of MSI High
Figure S3 from An Emerging Landscape for Canonical and Actionable Molecular Alterations in Primary and Metastatic Prostate Cancer
Authors: Dawson Nancy A. , Zibelman Matthew , Lindsay Timothy , Feldman Rebecca A. , Saul Michelle , Gatalica Zoran , Korn W. Michael , Heath Elisabeth I.
Published: April 2023

differential rates of mutations in primary and metastatic prostate cancers
Supplementary Materials from Decitabine Response in Breast Cancer Requires Efficient Drug Processing and Is Not Limited by Multidrug Resistance
Authors: Dahn Margaret L. , Cruickshank Brianne M. , Jackson Ainsleigh J. , Dean Cheryl , Holloway Ryan W. , Hall Steven R. , Coyle Krysta M. , Maillet Hillary , Waisman David M. , Goralski Kerry B. , Giacomantonio Carman A. , Weaver Ian C.G. , Marcato Paola
Published: April 2023

Additional figures, tables, and methods
Microarray decitabine-induced gene expression changes from Decitabine Response in Breast Cancer Requires Efficient Drug Processing and Is Not Limited by Multidrug Resistance
Authors: Dahn Margaret L. , Cruickshank Brianne M. , Jackson Ainsleigh J. , Dean Cheryl , Holloway Ryan W. , Hall Steven R. , Coyle Krysta M. , Maillet Hillary , Waisman David M. , Goralski Kerry B. , Giacomantonio Carman A. , Weaver Ian C.G. , Marcato Paola
Published: April 2023

Microarray gene expression analyses for MDA-MB-468, MDA-MB-231, and SUM159 cells after decitabine treatment
HM450 for genes with altered expression from Decitabine Response in Breast Cancer Requires Efficient Drug Processing and Is Not Limited by Multidrug Resistance
Authors: Dahn Margaret L. , Cruickshank Brianne M. , Jackson Ainsleigh J. , Dean Cheryl , Holloway Ryan W. , Hall Steven R. , Coyle Krysta M. , Maillet Hillary , Waisman David M. , Goralski Kerry B. , Giacomantonio Carman A. , Weaver Ian C.G. , Marcato Paola
Published: April 2023

HM450 DNA methylation B-values for genes up- or down-regulated by decitabine in MDA-MB-468, MDA-MB-231, or SUM159
Supplementary figure 2 from Novel Miniaturized Drug Conjugate Leverages HSP90-driven Tumor Accumulation to Overcome PI3K Inhibitor Delivery Challenges to Solid Tumors
Authors: Perino Samantha , Moreau Benoit , Freda Jessica , Cirello Amanda , White Brian H. , Quinn James M. , Kriksciukaite Kristina , Someshwar Ashwajith , Romagnoli Janel , Robinson Megan , Movassaghian Sara , Cipriani Tyler , Wooster Richard , Bilodeau Mark T. , Whalen Kerry A.
Published: April 2023

Supplementary figure 2 shows blood glucose levels in mice who have been dosed with a single dose of T-2143 over a 24 hour period.
Supplementary Synthesis Route from Novel Miniaturized Drug Conjugate Leverages HSP90-driven Tumor Accumulation to Overcome PI3K Inhibitor Delivery Challenges to Solid Tumors
Authors: Perino Samantha , Moreau Benoit , Freda Jessica , Cirello Amanda , White Brian H. , Quinn James M. , Kriksciukaite Kristina , Someshwar Ashwajith , Romagnoli Janel , Robinson Megan , Movassaghian Sara , Cipriani Tyler , Wooster Richard , Bilodeau Mark T. , Whalen Kerry A.
Published: April 2023

detailed and complete T-2143 synthesis route
Supplementary Figure S1 from Novel Miniaturized Drug Conjugate Leverages HSP90-driven Tumor Accumulation to Overcome PI3K Inhibitor Delivery Challenges to Solid Tumors
Authors: Perino Samantha , Moreau Benoit , Freda Jessica , Cirello Amanda , White Brian H. , Quinn James M. , Kriksciukaite Kristina , Someshwar Ashwajith , Romagnoli Janel , Robinson Megan , Movassaghian Sara , Cipriani Tyler , Wooster Richard , Bilodeau Mark T. , Whalen Kerry A.
Published: April 2023

Supplementary Figure S1 shows the pharmacokinetic profiles of T-2143 and T-2122
Supplementary Figure 4 from Novel Miniaturized Drug Conjugate Leverages HSP90-driven Tumor Accumulation to Overcome PI3K Inhibitor Delivery Challenges to Solid Tumors
Authors: Perino Samantha , Moreau Benoit , Freda Jessica , Cirello Amanda , White Brian H. , Quinn James M. , Kriksciukaite Kristina , Someshwar Ashwajith , Romagnoli Janel , Robinson Megan , Movassaghian Sara , Cipriani Tyler , Wooster Richard , Bilodeau Mark T. , Whalen Kerry A.
Published: April 2023

Supplementary figure 4 shows suppression of the PI3K pathway post a single dose of T-2143 in the LS174T xenograft model.
Supplementary Figure S2 from A Phase I Study of LY3009120, a Pan-RAF Inhibitor, in Patients with Advanced or Metastatic Cancer
Authors: Sullivan Ryan J. , Hollebecque Antoine , Flaherty Keith T. , Shapiro Geoffrey I. , Rodon Ahnert Jordi , Millward Michael J. , Zhang Wei , Gao Ling , Sykes Amanda , Willard Melinda D. , Yu Danni , Schade Andrew E. , Crowe KrisAnne , Flynn Daniel L. , Kaufman Michael D. , Henry James R. , Peng Sheng-Bin , Benhadji Karim A. , Conti Ilaria , Gordon Michael S. , Tiu Ramon V. , Hong David S.
Published: April 2023

Supplementary Figure S2 shows two cases of patients treated at the RP2D. IHC at Clarient for p-ERK, p27 and Ki-67 were assessed for PD effect using monoclonal rabbit phospho-p44/42 MAPK (ERK1/2), 20G11 Clone; monoclonal mouse anti-Ki67, MIB-1 clone; and monoclonal mouse anti-p27, SX53G8 clone. In (A), the patient is a 56-year old female patient with rectal neuroendocrine cancer who is KRAS and BRAF wild-type. No differences in staining for the 3 biomarkers were observed when baseline and Day 28 samples were compared. In (B), the patient is a 26-year old male patient with hepatocellular carcinoma with unknown mutational status. No differences in staining for Ki-67 or p27 were observed when baseline and Day 28 samples were compared. The p-ERK staining is poor quality and not interpretable. Abbreviations: IHC, immunohistochemistry; PD, pharmacodynamics; RP2D, recommended phase 2 dose
Table S4 from EMP2 Is a Novel Regulator of Stemness in Breast Cancer Cells
Authors: Dillard Christen , Kiyohara Meagan , Mah Vei , McDermott Sean P. , Bazzoun Dana , Tsui Jessica , Chan Ann M. , Haddad Ghassan , Pellegrini Matteo , Chang Yu-Ling , Elshimali Yahya , Wu Yanyuan , Vadgama Jaydutt V. , Kim Sara R. , Goodglick Lee , Law Samuel M. , Patel Deven D. , Dhawan Puneet , O'Brien Neil A. , Gordon Lynn K. , Braun Jonathan , Lazar Gary , Wicha Max S. , Wadehra Madhuri
Published: April 2023

Tumorsphere formation of breast cancer cells with modified EMP2 levels
Supplementary Tables 1-6 from ASTX029, a Novel Dual-mechanism ERK Inhibitor, Modulates Both the Phosphorylation and Catalytic Activity of ERK
Authors: Munck Joanne M. , Berdini Valerio , Bevan Luke , Brothwood Jessica L. , Castro Juan , Courtin Aurélie , East Charlotte , Ferraldeschi Roberta , Heightman Tom D. , Hindley Christopher J. , Kucia-Tran Justyna , Lyons John F. , Martins Vanessa , Muench Sandra , Murray Christopher W. , Norton David , O'Reilly Marc , Reader Michael , Rees David C. , Rich Sharna J. , Richardson Caroline J. , Shah Alpesh D. , Stanczuk Lukas , Thompson Neil T. , Wilsher Nicola E. , Woolford Alison J.-A. , Wallis Nicola G.
Published: April 2023

Supplementary tables 1-6 summarise the kinase panel screen data (1) mouse PK parameters (2) and further details of the anti-tumour activity (5) conferred by ASTX029, plus details of cell lines used in this study (3 and 4) and further details of the effects of ASTX029 and other MAPK inhibitors in models of MAPK resistance (6).
Table S2 from EMP2 Is a Novel Regulator of Stemness in Breast Cancer Cells
Authors: Dillard Christen , Kiyohara Meagan , Mah Vei , McDermott Sean P. , Bazzoun Dana , Tsui Jessica , Chan Ann M. , Haddad Ghassan , Pellegrini Matteo , Chang Yu-Ling , Elshimali Yahya , Wu Yanyuan , Vadgama Jaydutt V. , Kim Sara R. , Goodglick Lee , Law Samuel M. , Patel Deven D. , Dhawan Puneet , O'Brien Neil A. , Gordon Lynn K. , Braun Jonathan , Lazar Gary , Wicha Max S. , Wadehra Madhuri
Published: April 2023

Characteristics of 23 mammary and breast cancer cell lines.
Table S1 from EMP2 Is a Novel Regulator of Stemness in Breast Cancer Cells
Authors: Dillard Christen , Kiyohara Meagan , Mah Vei , McDermott Sean P. , Bazzoun Dana , Tsui Jessica , Chan Ann M. , Haddad Ghassan , Pellegrini Matteo , Chang Yu-Ling , Elshimali Yahya , Wu Yanyuan , Vadgama Jaydutt V. , Kim Sara R. , Goodglick Lee , Law Samuel M. , Patel Deven D. , Dhawan Puneet , O'Brien Neil A. , Gordon Lynn K. , Braun Jonathan , Lazar Gary , Wicha Max S. , Wadehra Madhuri
Published: April 2023

Selected functional pathways enriched with EMP2 mRNA based on TCGA data.
Supplementary Figures 1-7 from ASTX029, a Novel Dual-mechanism ERK Inhibitor, Modulates Both the Phosphorylation and Catalytic Activity of ERK
Authors: Munck Joanne M. , Berdini Valerio , Bevan Luke , Brothwood Jessica L. , Castro Juan , Courtin Aurélie , East Charlotte , Ferraldeschi Roberta , Heightman Tom D. , Hindley Christopher J. , Kucia-Tran Justyna , Lyons John F. , Martins Vanessa , Muench Sandra , Murray Christopher W. , Norton David , O'Reilly Marc , Reader Michael , Rees David C. , Rich Sharna J. , Richardson Caroline J. , Shah Alpesh D. , Stanczuk Lukas , Thompson Neil T. , Wilsher Nicola E. , Woolford Alison J.-A. , Wallis Nicola G.
Published: April 2023

Supplementary figures 1-7 show the effects of AST029 on ERK signalling in RAS-mutant cell lines (1) and tumour xenograft tissue (3), ASTX029 plasma PK linearity (2), ASTX029 activity in a cell line panel showing MAPK mutation status (4) the effects of ASTX029 on mouse body weight (5), PKPD effects of ASTX029 following b.i.d dosing to Colo205 tumour-bearing mice (6) and PD effects of ASTX029 following qd dosing to A375R tumour-bearing mice (7).
Supplementary Figure 1 from Hyaluronidase-Expressing Salmonella Effectively Targets Tumor-Associated Hyaluronic Acid in Pancreatic Ductal Adenocarcinoma
Authors: Ebelt Nancy D. , Zuniga Edith , Passi Kevin B. , Sobocinski Lukas J. , Manuel Edwin R.
Published: April 2023

Supplementary Figure 1 describes BHs expression in uninduced ST strains as well as the predicted localization of BHs. Viability of bHs-expressing ST strains is analyzed.
Supplementary Table from A Novel Combination Approach Targeting an Enhanced Protein Synthesis Pathway in MYC-driven (Group 3) Medulloblastoma
Authors: Chaturvedi Nagendra K. , Kling Matthew J. , Griggs Connor N. , Kesherwani Varun , Shukla Mamta , McIntyre Erin M. , Ray Sutapa , Liu Yutong , McGuire Timothy R. , Sharp J. Graham , Band Hamid , Joshi Shantaram S. , Coulter Don W.
Published: April 2023

Table S1. The list of genes whose expression were positively and strongly correlated with MYC expression in Group 3 MB.
Supplementary Figure Legends from Novel Humanized Mesothelin-Expressing Genetically Engineered Mouse Models Underscore Challenges in Delivery of Complex Therapeutics to Pancreatic Cancers
Authors: Hagerty Brendan , O'Sullivan T. Norene , Zhang Xianyu , Collins N. Keith , Custer Lawrence Wendi , Bassel Laura L. , Pate Nathan , Xu Jian , Guerin Theresa M. , Kozlov Serguei , Alewine Christine
Published: April 2023

Legends for the three Supplementary Figures.
Supplementary Figure from Luxeptinib (CG-806) Targets FLT3 and Clusters of Kinases Operative in Acute Myeloid Leukemia
Authors: Rice William G. , Howell Stephen B. , Zhang Hongying , Rastgoo Nasrin , Local Andrea , Kurtz Stephen E. , Lo Pierrette , Bottomly Daniel , Wilmot Beth , McWeeney Shannon K. , Druker Brian J. , Tyner Jeffrey W.
Published: April 2023

Supplementary Figure from Luxeptinib (CG-806) Targets FLT3 and Clusters of Kinases Operative in Acute Myeloid Leukemia
Supplementary Figure S1 from Ubiquitinated PCNA Drives USP1 Synthetic Lethality in Cancer
Authors: Simoneau Antoine , Engel Justin L. , Bandi Madhavi , Lazarides Katherine , Liu Shangtao , Meier Samuel R. , Choi Ashley H. , Zhang Hongxiang , Shen Binzhang , Martires Lauren , Gotur Deepali , Pham Truc V. , Li Fang , Gu Lina , Gong Shanzhong , Zhang Minjie , Wilker Erik , Pan Xuewen , Whittington Douglas A. , Throner Scott , Maxwell John P. , Chen Yingnan , Yu Yi , Huang Alan , Andersen Jannik N. , Feng Tianshu
Published: April 2023

I-138 inhibits USP1-UAF1 - related to Figure 1
Supplementary Figure from External Validation of Association of Baseline Circulating Tumor Cell Counts with Survival Outcomes in Men with Metastatic Castration-Sensitive Prostate Cancer
Authors: Swami Umang , Sayegh Nicolas , Jo Yeonjung , Haaland Benjamin , McFarland Taylor Ryan , Nussenzveig Roberto H. , Goel Divyam , Sirohi Deepika , Hahn Andrew W. , Maughan Benjamin L. , Goldkorn Amir , Agarwal Neeraj
Published: April 2023

Supplementary Figure from External Validation of Association of Baseline Circulating Tumor Cell Counts with Survival Outcomes in Men with Metastatic Castration-Sensitive Prostate Cancer
Supplementary Table from Inhibition of NF-κB DNA Binding Suppresses Myeloma Growth via Intracellular Redox and Tumor Microenvironment Modulation
Authors: Bariana Manpreet , Cassella Elena , Rateshwar Janice , Ouk Samedy , Liou Hsiou-Chi , Heller Claudia , Colorado Iriana , Feinman Rena , Makhdoom Ali , Siegel David S. , Heller Glenn , Tuckett Andrea , Mondello Patrizia , Zakrzewski Johannes L.
Published: April 2023

Supplementary Table from Inhibition of NF-κB DNA Binding Suppresses Myeloma Growth via Intracellular Redox and Tumor Microenvironment Modulation
Supplementary Figure from Inhibition of the Translation Initiation Factor eIF4A Enhances Tumor Cell Radiosensitivity
Authors: Lehman Stacey L. , Wechsler Theresa , Schwartz Kayla , Brown Lauren E. , Porco John A. , Devine William G. , Pelletier Jerry , Shankavaram Uma T. , Camphausen Kevin , Tofilon Philip J.
Published: April 2023

Supplementary Figure from Inhibition of the Translation Initiation Factor eIF4A Enhances Tumor Cell Radiosensitivity
Supplementary Data from Inhibition of the Translation Initiation Factor eIF4A Enhances Tumor Cell Radiosensitivity
Authors: Lehman Stacey L. , Wechsler Theresa , Schwartz Kayla , Brown Lauren E. , Porco John A. , Devine William G. , Pelletier Jerry , Shankavaram Uma T. , Camphausen Kevin , Tofilon Philip J.
Published: April 2023

Supplementary Data from Inhibition of the Translation Initiation Factor eIF4A Enhances Tumor Cell Radiosensitivity
Supplementary Data from Sirpiglenastat (DRP-104) Induces Antitumor Efficacy through Direct, Broad Antagonism of Glutamine Metabolism and Stimulation of the Innate and Adaptive Immune Systems
Authors: Yokoyama Yumi , Estok Thomas M. , Wild Robert
Published: April 2023

Supplementary Data from Sirpiglenastat (DRP-104) Induces Antitumor Efficacy through Direct, Broad Antagonism of Glutamine Metabolism and Stimulation of the Innate and Adaptive Immune Systems
Supplementary Methods from Discovery of a Novel ATP-Competitive MEK Inhibitor DS03090629 that Overcomes Resistance Conferred by BRAF Overexpression in BRAF-Mutated Melanoma
Authors: Takano Kohei , Munehira Yoichi , Hatanaka Mana , Murakami Ryo , Shibata Yoshihiro , Shida Takeshi , Takeuchi Kosuke , Takechi Sho , Tabata Toshiki , Shimada Takashi , Kishikawa Shuhei , Matsui Yumi , Ubukata Osamu , Seki Takahiko , Kaneta Yasuyuki
Published: April 2023

Supplementary Methods from Discovery of a Novel ATP-Competitive MEK Inhibitor DS03090629 that Overcomes Resistance Conferred by BRAF Overexpression in BRAF-Mutated Melanoma
Supplementary Table from Ovarian Cancers with Low CIP2A Tumor Expression Constitute an APR-246–Sensitive Disease Subtype
Authors: Cvrljevic Anna N. , Butt Umar , Huhtinen Kaisa , Grönroos Tove J. , Böckelman Camilla , Lassus Heini , Butzow Ralf , Haglund Caj , Kaipio Katja , Arsiola Tiina , Laajala Teemu D. , Connolly Denise C. , Ristimäki Ari , Carpen Olli , Pouwels Jeroen , Westermarck Jukka
Published: April 2023

Supplementary Table from Ovarian Cancers with Low CIP2A Tumor Expression Constitute an APR-246–Sensitive Disease Subtype
Figure S7 from IGF1R Inhibition Enhances the Therapeutic Effects of Gq/11 Inhibition in Metastatic Uveal Melanoma Progression
Authors: Lapadula Dominic , Lam Bao , Terai Mizue , Sugase Takahito , Tanaka Ryota , Farias Eduardo , Kadamb Rama , Lopez-Anton Melisa , Heine Christian C. , Modasia Bhavik , Aguirre-Ghiso Julio A. , Aplin Andrew E. , Sato Takami , Benovic Jeffrey L.
Published: April 2023

Figure S7: Quantification of UM001 cell western blots from Fig. 7. Bands were normalized to GAPDH quantification. Error bars represent the mean + SEM from 3 independent experiments. P < 0.05 (*), P < 0.005 (**), P < 0.0005 (***), P < 0.0001 (****), Two-way ANOVA.
Figure S5 from IGF1R Inhibition Enhances the Therapeutic Effects of Gq/11 Inhibition in Metastatic Uveal Melanoma Progression
Authors: Lapadula Dominic , Lam Bao , Terai Mizue , Sugase Takahito , Tanaka Ryota , Farias Eduardo , Kadamb Rama , Lopez-Anton Melisa , Heine Christian C. , Modasia Bhavik , Aguirre-Ghiso Julio A. , Aplin Andrew E. , Sato Takami , Benovic Jeffrey L.
Published: April 2023

Figure S5: Quantification of 92.1 cell western blots from Fig. 7. Bands were normalized to GAPDH quantification. Error bars represent the mean + SEM from 3 independent experiments. P < 0.05 (*), P < 0.005 (**), P < 0.0005 (***), P < 0.0001 (****), Two-way ANOVA.
Figure S2 from IGF1R Inhibition Enhances the Therapeutic Effects of Gq/11 Inhibition in Metastatic Uveal Melanoma Progression
Authors: Lapadula Dominic , Lam Bao , Terai Mizue , Sugase Takahito , Tanaka Ryota , Farias Eduardo , Kadamb Rama , Lopez-Anton Melisa , Heine Christian C. , Modasia Bhavik , Aguirre-Ghiso Julio A. , Aplin Andrew E. , Sato Takami , Benovic Jeffrey L.
Published: April 2023

Figure S2: YM treatment rapidly decreases MAPK signaling in OMM1.3 cells. OMM1.3 cells were treated with 1 M YM for up to 1 hour or DMSO for 1 hour and cell lysates were immunoblotted for ERK2 and pERK1/2. Error bars represent the mean + SEM from 3 independent experiments. P < 0.05 (*), P < 0.005 (**), P < 0.0001 (****) for differences between control and YM treated pERK to ERK ratio, One-way ANOVA.
Supplementary Table from Decreased DNA Damage and Improved p53 Specificity of RITA Analogs
Authors: Zhan Yue , Zhou Xiaolei , Peuget Sylvain , Singh Madhurendra , Peyser Brian D. , Fan Zhimin , Selivanova Galina
Published: April 2023

Supplementary Table from Decreased DNA Damage and Improved p53 Specificity of RITA Analogs
Supplementary Figure from Decreased DNA Damage and Improved p53 Specificity of RITA Analogs
Authors: Zhan Yue , Zhou Xiaolei , Peuget Sylvain , Singh Madhurendra , Peyser Brian D. , Fan Zhimin , Selivanova Galina
Published: April 2023

Supplementary Figure from Decreased DNA Damage and Improved p53 Specificity of RITA Analogs
Fig S6 from A Bispecific METxMET Antibody–Drug Conjugate with Cleavable Linker Is Processed in Recycling and Late Endosomes
Authors: Perez Bay Andres E. , Faulkner Devon , DaSilva John O. , Young Tara M. , Yang Katie , Giurleo Jason T. , Ma Dangshe , Delfino Frank J. , Olson William C. , Thurston Gavin , Daly Christopher , Andreev Julian
Published: April 2023

Dynasore
Fig S5 from A Bispecific METxMET Antibody–Drug Conjugate with Cleavable Linker Is Processed in Recycling and Late Endosomes
Authors: Perez Bay Andres E. , Faulkner Devon , DaSilva John O. , Young Tara M. , Yang Katie , Giurleo Jason T. , Ma Dangshe , Delfino Frank J. , Olson William C. , Thurston Gavin , Daly Christopher , Andreev Julian
Published: April 2023

Rabs KO Endocytosis
Fig S3 from A Bispecific METxMET Antibody–Drug Conjugate with Cleavable Linker Is Processed in Recycling and Late Endosomes
Authors: Perez Bay Andres E. , Faulkner Devon , DaSilva John O. , Young Tara M. , Yang Katie , Giurleo Jason T. , Ma Dangshe , Delfino Frank J. , Olson William C. , Thurston Gavin , Daly Christopher , Andreev Julian
Published: April 2023

In vivo processing
Fig S2 from A Bispecific METxMET Antibody–Drug Conjugate with Cleavable Linker Is Processed in Recycling and Late Endosomes
Authors: Perez Bay Andres E. , Faulkner Devon , DaSilva John O. , Young Tara M. , Yang Katie , Giurleo Jason T. , Ma Dangshe , Delfino Frank J. , Olson William C. , Thurston Gavin , Daly Christopher , Andreev Julian
Published: April 2023

Endosomal itinerary
Fig S1 from A Bispecific METxMET Antibody–Drug Conjugate with Cleavable Linker Is Processed in Recycling and Late Endosomes
Authors: Perez Bay Andres E. , Faulkner Devon , DaSilva John O. , Young Tara M. , Yang Katie , Giurleo Jason T. , Ma Dangshe , Delfino Frank J. , Olson William C. , Thurston Gavin , Daly Christopher , Andreev Julian
Published: April 2023

Recycling rounds
Supplementary Data from BT8009; A Nectin-4 Targeting Bicycle Toxin Conjugate for Treatment of Solid Tumors
Authors: Rigby Michael , Bennett Gavin , Chen Liuhong , Mudd Gemma E. , Harrison Helen , Beswick Paul J. , Van Rietschoten Katerine , Watcham Sophie M. , Scott Heather S. , Brown Amy N. , Park Peter U. , Campbell Carly , Haines Eric , Lahdenranta Johanna , Skynner Michael J. , Jeffrey Phil , Keen Nicholas , Lee Kevin
Published: April 2023

Supplementary Data from BT8009; A Nectin-4 Targeting Bicycle Toxin Conjugate for Treatment of Solid Tumors
Supplementary Data from Colchicine-Binding Site Agent CH-2-77 as a Potent Tubulin Inhibitor Suppressing Triple-Negative Breast Cancer
Authors: Deng Shanshan , Krutilina Raisa I. , Hartman Kelli L. , Chen Hao , Parke Deanna N. , Wang Rui , Mahmud Foyez , Ma Dejian , Lukka Pradeep B. , Meibohm Bernd , Seagroves Tiffany N. , Miller Duane D. , Li Wei
Published: April 2023

Supplementary Data from Colchicine-Binding Site Agent CH-2-77 as a Potent Tubulin Inhibitor Suppressing Triple-Negative Breast Cancer
Supplementary Data from Ovarian Cancers with Low CIP2A Tumor Expression Constitute an APR-246–Sensitive Disease Subtype
Authors: Cvrljevic Anna N. , Butt Umar , Huhtinen Kaisa , Grönroos Tove J. , Böckelman Camilla , Lassus Heini , Butzow Ralf , Haglund Caj , Kaipio Katja , Arsiola Tiina , Laajala Teemu D. , Connolly Denise C. , Ristimäki Ari , Carpen Olli , Pouwels Jeroen , Westermarck Jukka
Published: April 2023

Supplementary Data from Ovarian Cancers with Low CIP2A Tumor Expression Constitute an APR-246–Sensitive Disease Subtype
Supplementary Figure 1 from Current Status and Challenges of Vaccination Therapy for Glioblastoma
Authors: Hosseinalizadeh Hamed , Rahmati Mohammad , Ebrahimi Ammar , O'Connor Roddy S.
Published: April 2023

Current status and challenges of vaccination therapy for glioblastoma.
Supplementary Figure S5 from Efficacious Combination Drug Treatment for Colorectal Cancer That Overcomes Resistance to KRAS G12C Inhibitors
Authors: Matsubara Hiroyuki , Miyoshi Hiroyuki , Kakizaki Fumihiko , Morimoto Tomonori , Kawada Kenji , Yamamoto Takehito , Obama Kazutaka , Sakai Yoshiharu , Taketo Makoto Mark
Published: April 2023

Supplementary Figure S5
Supplementary Figure S4 from Efficacious Combination Drug Treatment for Colorectal Cancer That Overcomes Resistance to KRAS G12C Inhibitors
Authors: Matsubara Hiroyuki , Miyoshi Hiroyuki , Kakizaki Fumihiko , Morimoto Tomonori , Kawada Kenji , Yamamoto Takehito , Obama Kazutaka , Sakai Yoshiharu , Taketo Makoto Mark
Published: April 2023

Suppl. Fig. S4 with its legend on page 2
Supplementary Figure S3 from Efficacious Combination Drug Treatment for Colorectal Cancer That Overcomes Resistance to KRAS G12C Inhibitors
Authors: Matsubara Hiroyuki , Miyoshi Hiroyuki , Kakizaki Fumihiko , Morimoto Tomonori , Kawada Kenji , Yamamoto Takehito , Obama Kazutaka , Sakai Yoshiharu , Taketo Makoto Mark
Published: April 2023

Suppl. Fig. S3 with its legend on page 2
Supplementary Figure S1 from Efficacious Combination Drug Treatment for Colorectal Cancer That Overcomes Resistance to KRAS G12C Inhibitors
Authors: Matsubara Hiroyuki , Miyoshi Hiroyuki , Kakizaki Fumihiko , Morimoto Tomonori , Kawada Kenji , Yamamoto Takehito , Obama Kazutaka , Sakai Yoshiharu , Taketo Makoto Mark
Published: April 2023

Suppl. Fig. S1.
Table S1-S3 from Liposome-Encapsulated Eribulin Shows Enhanced Antitumor Activity over Eribulin for Combination Therapy with Anti–PD-1 Antibody
Authors: Niwa Yuki , Adachi Keito , Tabata Kimiyo , Ishida Ryoga , Hotta Koichiro , Ishida Tomomi , Mano Yuji , Ozawa Yoichi , Minoshima Yukinori , Funahashi Yasuhiro , Semba Taro
Published: April 2023

Antibody lists used in the flow cytometric analysis
Supplementary Figures from Liposome-Encapsulated Eribulin Shows Enhanced Antitumor Activity over Eribulin for Combination Therapy with Anti–PD-1 Antibody
Authors: Niwa Yuki , Adachi Keito , Tabata Kimiyo , Ishida Ryoga , Hotta Koichiro , Ishida Tomomi , Mano Yuji , Ozawa Yoichi , Minoshima Yukinori , Funahashi Yasuhiro , Semba Taro
Published: April 2023

Fig S1 shows isotype control has no antitumor activity. Fig S2 shows gating strategy for flow cytometric analysis of TILs. Fig S3 shows induction of ICAM-1 by eribulin. Fig S4 shows establishment of P-gp KO cell lines and ICD activity of eribulin. Fig S5 shows dose-dependent antitumor activity of eribulin-LF + anti-PD-1 Ab. Fig S6 shows PK analysis of eribulin and eribulin-LF in plasma and tumor. Fig S7 shows immunomodulatory activity of eribulin in different 3 regimens. Fig S8 shows TIL population changes not included in the main figures. Fig S9 shows activation of IFN signature by eribulin-LF.
Supplementary Figure Legends from Liposome-Encapsulated Eribulin Shows Enhanced Antitumor Activity over Eribulin for Combination Therapy with Anti–PD-1 Antibody
Authors: Niwa Yuki , Adachi Keito , Tabata Kimiyo , Ishida Ryoga , Hotta Koichiro , Ishida Tomomi , Mano Yuji , Ozawa Yoichi , Minoshima Yukinori , Funahashi Yasuhiro , Semba Taro
Published: April 2023

Legends for supplementary figures S1-S9
Figure S8 from Inhibition of LILRB2 by a Novel Blocking Antibody Designed to Reprogram Immunosuppressive Macrophages to Drive T-Cell Activation in Tumors
Authors: Umiker Ben , Hashambhoy-Ramsay Yasmin , Smith Jeff , Rahman Tanzila , Mueller Amy , Davidson Rachel , Meyer Christina , Patankar Gayatri , Alam Mohammad Murshid , Jaffe Sarah , Krukenberg Kristin , Goodman Allison , Spaulding Vikki , Priess Michelle , Dhaneshwar Abha , Wong Masie , Diiorio Alexa , O'Malley Kristin , McGrath Lara , Willer Margaret , Pepper Lauren , Gostissa Monica , Kis-Toth Katalin , Wiederschain Dmitri , Cohen Heather , Shaffer Donald R.
Published: April 2023

Changes in gene expression by JTX-8064 in both macrophages and dendritic cells 6 days on treatment during differentiation
Supplementary Figures from SGN-CD228A Is an Investigational CD228-Directed Antibody–Drug Conjugate with Potent Antitumor Activity across a Wide Spectrum of Preclinical Solid Tumor Models
Authors: Mazahreh Rebecca , Mason Marsha L. , Gosink John J. , Olson Devra J. , Thurman Robert , Hale Christopher , Westendorf Lori , Pires Thomas A. , Leiske Christopher I. , Carlson Markus , Nguyen Liem T. , Cochran Julia H. , Okeley Nicole M. , Yumul Roma , Jin Steven , Stone Ivan J. , Sahetya Disha , Nesterova Albina , Allred Sean , Hensley Kelly M. , Hu Rachael , Lawrence Robert , Lewis Timothy S. , Sandall Sharsti
Published: April 2023

Figures S1-S9
Figure S6 from Inhibition of LILRB2 by a Novel Blocking Antibody Designed to Reprogram Immunosuppressive Macrophages to Drive T-Cell Activation in Tumors
Authors: Umiker Ben , Hashambhoy-Ramsay Yasmin , Smith Jeff , Rahman Tanzila , Mueller Amy , Davidson Rachel , Meyer Christina , Patankar Gayatri , Alam Mohammad Murshid , Jaffe Sarah , Krukenberg Kristin , Goodman Allison , Spaulding Vikki , Priess Michelle , Dhaneshwar Abha , Wong Masie , Diiorio Alexa , O'Malley Kristin , McGrath Lara , Willer Margaret , Pepper Lauren , Gostissa Monica , Kis-Toth Katalin , Wiederschain Dmitri , Cohen Heather , Shaffer Donald R.
Published: April 2023

A Neutrophil activation assay which measures the frequency CD11b high expression by flow on neutrophils isolated from whole blood
Figure S2 from Inhibition of LILRB2 by a Novel Blocking Antibody Designed to Reprogram Immunosuppressive Macrophages to Drive T-Cell Activation in Tumors
Authors: Umiker Ben , Hashambhoy-Ramsay Yasmin , Smith Jeff , Rahman Tanzila , Mueller Amy , Davidson Rachel , Meyer Christina , Patankar Gayatri , Alam Mohammad Murshid , Jaffe Sarah , Krukenberg Kristin , Goodman Allison , Spaulding Vikki , Priess Michelle , Dhaneshwar Abha , Wong Masie , Diiorio Alexa , O'Malley Kristin , McGrath Lara , Willer Margaret , Pepper Lauren , Gostissa Monica , Kis-Toth Katalin , Wiederschain Dmitri , Cohen Heather , Shaffer Donald R.
Published: April 2023

Example gating strategy for tumor samples in order to acquire CD163 and LILRB2 + cells
Figure S4 from Bepotastine Sensitizes Ovarian Cancer to PARP Inhibitors through Suppressing NF-κB–Triggered SASP in Cancer-Associated Fibroblasts
Authors: Jin Ping , Li Xin , Xia Yu , Li Huayi , Li Xiaoting , Yang Zong-Yuan , Wang Zhen , Xu Cheng , Fang Tian , Zhou Dongchen , Xiong Xiaoming , Wang Si-Yuan , Xu Sen , Gao Qinglei
Published: April 2023

Figure S4, related to Fig 6
Figure S3 from Bepotastine Sensitizes Ovarian Cancer to PARP Inhibitors through Suppressing NF-κB–Triggered SASP in Cancer-Associated Fibroblasts
Authors: Jin Ping , Li Xin , Xia Yu , Li Huayi , Li Xiaoting , Yang Zong-Yuan , Wang Zhen , Xu Cheng , Fang Tian , Zhou Dongchen , Xiong Xiaoming , Wang Si-Yuan , Xu Sen , Gao Qinglei
Published: April 2023

Figure S3, related to Fig 4
Figure S2 from Bepotastine Sensitizes Ovarian Cancer to PARP Inhibitors through Suppressing NF-κB–Triggered SASP in Cancer-Associated Fibroblasts
Authors: Jin Ping , Li Xin , Xia Yu , Li Huayi , Li Xiaoting , Yang Zong-Yuan , Wang Zhen , Xu Cheng , Fang Tian , Zhou Dongchen , Xiong Xiaoming , Wang Si-Yuan , Xu Sen , Gao Qinglei
Published: April 2023

Figure S2, related to Fig 2
Figure S1 from Bepotastine Sensitizes Ovarian Cancer to PARP Inhibitors through Suppressing NF-κB–Triggered SASP in Cancer-Associated Fibroblasts
Authors: Jin Ping , Li Xin , Xia Yu , Li Huayi , Li Xiaoting , Yang Zong-Yuan , Wang Zhen , Xu Cheng , Fang Tian , Zhou Dongchen , Xiong Xiaoming , Wang Si-Yuan , Xu Sen , Gao Qinglei
Published: April 2023

Figure S1, related to Fig 1
Supplementary Data from A Phase I Study of Combination Olaparib and Radium-223 in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) with Bone Metastases (COMRADE)
Authors: Pan Elizabeth , Xie Wanling , Ajmera Archana , Araneta Arlene , Jamieson Christina , Folefac Edmund , Hussain Arif , Kyriakopoulos Christos E. , Olson Adam , Parikh Mamta , Parikh Rahul , Saraiya Biren , Ivy S. Percy , Van Allen Eliezer M. , Lindeman Neal I. , Kochupurakkal Bose S. , Shapiro Geoffrey I. , McKay Rana R.
Published: April 2023

Supplementary methods, Tables S1-S3, Figures S1 and S2
Supplementary Table 2 from Payload-Binding Fab Fragments Increase the Therapeutic Index of MMAE Antibody–Drug Conjugates
Authors: Bordeau Brandon M. , Nguyen Toan Duc , Polli Joseph Ryan , Chen Ping , Balthasar Joseph P.
Published: April 2023

Supplementary Table 2
Supplementary Table 1 from Payload-Binding Fab Fragments Increase the Therapeutic Index of MMAE Antibody–Drug Conjugates
Authors: Bordeau Brandon M. , Nguyen Toan Duc , Polli Joseph Ryan , Chen Ping , Balthasar Joseph P.
Published: April 2023

Supplementary Table 1
Supplementary Figures from Griseofulvin Radiosensitizes Non–Small Cell Lung Cancer Cells and Activates cGAS
Authors: Wang Xing , Raman Natasha , Lemtiri-Chlieh Ghali , Chang Jinhee , Jagtap Shreya , Chowdhury Dipanwita Dutta , Ballew Matthew , Carrieri Francesca Anna , Nguyen Triet , Nugent Katriana , Peck Travis , Levine Michelle S. , Chan Aaron , Lam Christine , Malek Reem , Hoang Tung , Phillips Ryan , Cheng ZhuoAn , Taparra Kekoa , Connis Nick , Hann Christine L. , Holland Andrew , Tran Phuoc T. , Lafargue Audrey , Wang Hailun
Published: April 2023

Figure S1 shows basal centrosome amplification in cell lines. Figure S2 shows the effect of GF on cell viability. Figure S3 shows HSET expression in cell lines. Figure S4 shows the effect of GF on clonogenic potential after RT. Figure S5 shows the induction of micronuclei after GF and/or RT. Figure S6 shows the expression of IFN-β after GF and/or RT.